Moreover, to further investigate whether ERK5 could influence the primary tumor cell growth, we collected PDCs from patients with different EGFR mutational status (Glioma#8, #14: both EGFR mutations and amplifications; Glioma#12, #22: WT) (Methods). This evidence concerns the gene EGFR and central nervous system cancer.